<?xml version='1.0' encoding='utf-8'?>
<document id="31050085"><sentence text="Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited."><entity charOffset="15-29" id="DDI-PubMed.31050085.s1.e0" text="metoclopramide" /></sentence><sentence text="Metoclopramide is primarily a dopamine receptor antagonist, with 5HT3 receptor antagonist and 5HT4 receptor agonist activity, and used as an antiemetic and gastroprokinetic since almost 50 years"><entity charOffset="0-14" id="DDI-PubMed.31050085.s2.e0" text="Metoclopramide" /><entity charOffset="30-38" id="DDI-PubMed.31050085.s2.e1" text="dopamine" /><pair ddi="false" e1="DDI-PubMed.31050085.s2.e0" e2="DDI-PubMed.31050085.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31050085.s2.e0" e2="DDI-PubMed.31050085.s2.e1" /></sentence><sentence text=" Regulatory authorities issued restrictions and recommendations regarding long-term use of the drug at oral doses exceeding 10 mg 3-4 times daily because of the risk for development of tardive dyskinesia" /><sentence text=" The aim of our study was to review mechanism(s) of action and pharmacokinetic-pharmacodynamic properties of metoclopramide, as well as the risk of metoclopramide-induced tardive dyskinesia, factors that may change drug exposure in humans, and to summarize the clinical context for appropriate use of the drug"><entity charOffset="109-123" id="DDI-PubMed.31050085.s4.e0" text="metoclopramide" /><entity charOffset="148-162" id="DDI-PubMed.31050085.s4.e1" text="metoclopramide" /><pair ddi="false" e1="DDI-PubMed.31050085.s4.e0" e2="DDI-PubMed.31050085.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31050085.s4.e0" e2="DDI-PubMed.31050085.s4.e1" /></sentence><sentence text="" /><sentence text="A PubMed, Google Scholar, and Cross Reference search was done using the key words and combined searches: drug-drug interaction, gastroparesis, metoclopramide, natural history, pharmacokinetics, pharmacodynamics, drug-drug interaction, outcome, risk factors, tardive dyskinesia"><entity charOffset="143-157" id="DDI-PubMed.31050085.s6.e0" text="metoclopramide" /></sentence><sentence text="" /><sentence text="Data show that the risk of tardive dyskinesia from metoclopramide is low, in the range of 0"><entity charOffset="51-65" id="DDI-PubMed.31050085.s8.e0" text="metoclopramide" /></sentence><sentence text="1% per 1000 patient years" /><sentence text=" This is far below a previously estimated 1%-10% risk suggested in treatment guidelines by regulatory authorities" /><sentence text=" High-risk groups are elderly females, diabetics, patients with liver or kidney failure, and patients with concomitant antipsychotic drug therapy, which reduces the threshold for neurological complications" /><sentence text="" /><sentence text="The risk of tardive dyskinesia due to metoclopramide is far below approximated numbers in treatment guidelines"><entity charOffset="38-52" id="DDI-PubMed.31050085.s13.e0" text="metoclopramide" /></sentence><sentence text=" This risk and the influence of known risk factors should be considered when starting a course of metoclopramide for treatment of gastroparesis"><entity charOffset="98-112" id="DDI-PubMed.31050085.s14.e0" text="metoclopramide" /></sentence><sentence text="" /></document>